Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Carcinogen Self-Inspection Survey Suggest 10% of Products at Risk: MHLW
April 22, 2024
- More Unexpected Substances in Kobayashi’s Beni-Koji Supplements: MHLW
April 22, 2024
- Japan to Discard 240 Million COVID Shots, but Says Purchase Wasn’t a Waste
April 22, 2024
- Japan Ups Efforts to Better Communicate Pricing, Regulations to Overseas: Official
April 19, 2024
- MHLW Panel Sets Topics for PMD Act Amendment; Pediatrics, Drug Loss on Agenda
April 19, 2024
- Japan Govt Sued for Lack of Information on COVID Vaccine Risks
April 18, 2024
- MOF Ramps Up Push for Use of Cost-Effectiveness Assessment in Reimbursement Decisions
April 17, 2024
- PMDA Stepping Up Generic Compliance Inspections from August Approvals
April 16, 2024
- 14 Makers Picked for Health Minister-Championed Subsidy Program for Cough Meds, Essential Drugs
April 15, 2024
- Japan to Discuss Orphan Designation for Cannabidiol, 2 More Drugs
April 15, 2024
- Japan Might Approve 1st Eylea Biosimilar by June, but Not AMD Use
April 15, 2024
- Japan Will Persistently Urge China to Release Detained Astellas Employee: Govt
April 12, 2024
- Alexion’s Voydeya Marks 1st Application of “Early Launch Premium,” but Rate Fully Axed
April 11, 2024
- Lagevrio to Get 8.2% Price Cut in July, 2.7% for Kerendia: CEA
April 11, 2024
- Average PMP Rate Hits Record Low at 1.2% in FY2024: MHLW
April 11, 2024
- Nobelpharma, Argenx Challenged Initial Pricing for New Meds; Claims Partially Accepted
April 11, 2024
- Argenx’s gMG Therapy Vyvdura OK’ed for Self-Injection
April 11, 2024
- Label Revision Ordered for 3 Beta Blockers to Delete Contraindication in Pregnant Women
April 10, 2024
- Fanconi Syndrome Found in Majority of Health Damages Tied to Beni-Koji Supplements
April 10, 2024
- LDP Healthcare Clique Urges Rethink of Rationale for Off-Year Drug Price Revisions
April 10, 2024
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…